In fact, several immunotherapies using autologous DC/Gal in clinical trials of solid tumor and hematological malignancies have indicated the importance of IFN-γ-producing iNKT cells and NK cell activation (Figure 1). This evidence concerns the gene IFNG and hematologic disorder.